Primary Biliary Cirrhosis beyond Ursodeoxycholic Acid

Seminars in Liver Disease

Volumn 36, Issue 1, 2016, Pages 15-26

  Corpechot, Christophe ^a,b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b HÔPITAL SAINT ANTOINE   (France)

Author keywords

bezafibrate; budesonide; farnesoid X receptor; fenofibrate; fibroblast growth factor 19; obeticholic acid; peroxisome proliferating associated receptor; pregnane X receptor

Indexed keywords

BUDESONIDE; FIBRIC ACID DERIVATIVE; OBETICHOLIC ACID; URSODEOXYCHOLIC ACID; CHOLAGOGUE;

ARTICLE; CLINICAL PRACTICE; DRUG INDICATION; HUMAN; PATIENT SELECTION; PRACTICE GUIDELINE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; ADVERSE EFFECTS; ANIMAL; DRUG EFFECTS; LIVER; LIVER CIRRHOSIS, BILIARY; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; CHOLAGOGUES AND CHOLERETICS; HUMANS; LIVER; LIVER CIRRHOSIS, BILIARY; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 84958161655     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0035-1571273     Document Type: Article

References (78)

1. European Association for the Study of the Liver EASL Clinical Practice Guidelines: Management of cholestatic liver diseases. J Hepatol: 2009; 51 2 237 267
2. Lindor K. D., Gershwin M. E., Poupon R., Kaplan M., Bergasa N. V., Heathcote E. J.; American Association for Study of Liver Diseases. Primary biliary cirrhosis. Hepatology: 2009; 50 1 291 308
3. ter Borg P. C., Schalm S. W., Hansen B. E., van Buuren H. R.; Dutch PBC Study Group. Prognosis of ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients. Am J Gastroenterol: 2006; 101 9 2044 2050
4. Parés A., Caballería L., Rodés J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology: 2006; 130 3 715 720
5. Corpechot C., Abenavoli L., Rabahi N., et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology: 2008; 48 3 871 877
6. Lammers W. J., van Buuren H. R., Hirschfield G. M., et al. Global PBC Study Group. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: An international follow-up study. Gastroenterology: 2014; 147 6 1338 49.e5, quiz e15
7. Trivedi P. J., Bruns T., Cheung A., et al. Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response. J Hepatol: 2014; 60 6 1249 1258
8. Leuschner M., Maier K. P., Schlichting J., et al. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: Results of a prospective double-blind trial. Gastroenterology: 1999; 117 4 918 925
9. Iwasaki S., Ohira H., Nishiguchi S., et al. Study Group of Intractable Liver Diseases for Research on a Specific Disease, Health Science Research Grant, Ministry of Health, Labour and Welfare of Japan. The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study. Hepatol Res: 2008; 38 6 557 564
10. Hirschfield G. M., Mason A., Luketic V., et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology: 2015; 148 4 751 61.e8
11. Corpechot C., Chazouillères O., Poupon R. Early primary biliary cirrhosis: Biochemical response to treatment and prediction of long-term outcome. J Hepatol: 2011; 55 6 1361 1367
12. Floreani A., Cazzagon N., Martines D., Cavalletto L., Baldo V., Chemello L. Performance and utility of transient elastography and noninvasive markers of liver fibrosis in primary biliary cirrhosis. Dig Liver Dis: 2011; 43 11 887 892
13. Corpechot C., Carrat F., Poujol-Robert A., et al. Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. Hepatology: 2012; 56 1 198 208
14. Carbone M., Mells G. F., Pells G., et al. UK PBC Consortium. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. Gastroenterology: 2013; 144 3 560 569.e7, quiz e13-e14
15. Quarneti C., Muratori P., Lalanne C., et al. Fatigue and pruritus at onset identify a more aggressive subset of primary biliary cirrhosis. Liver Int: 2015; 35 2 636 641
16. Chazouillères O., Wendum D., Serfaty L., Montembault S., Rosmorduc O., Poupon R. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: Clinical features and response to therapy. Hepatology: 1998; 28 2 296 301
17. Heurgué A., Vitry F., Diebold M. D., et al. Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: A retrospective study of 115 cases of autoimmune liver disease. Gastroenterol Clin Biol: 2007; 31 1 17 25
18. Joshi S., Cauch-Dudek K., Wanless I. R., et al. Primary biliary cirrhosis with additional features of autoimmune hepatitis: Response to therapy with ursodeoxycholic acid. Hepatology: 2002; 35 2 409 413
19. Chazouillères O., Poupon R. Ursodeoxycholic acid and primary biliary cirrhosis with features of autoimmune hepatitis. Hepatology: 2002; 36 4 Pt 1 1026 1027, author reply 1027
20. Ozaslan E., Efe C., Akbulut S., et al. Therapy response and outcome of overlap syndromes: Autoimmune hepatitis and primary biliary cirrhosis compared to autoimmune hepatitis and autoimmune cholangitis. Hepatogastroenterology: 2010; 57 99-100 441 446
21. Corpechot C., Carrat F., Poupon R., Poupon R. E. Primary biliary cirrhosis: Incidence and predictive factors of cirrhosis development in ursodiol-treated patients. Gastroenterology: 2002; 122 3 652 658
22. Carbone M., Sharpe S. J., Heneghan M. A., et al. Histological stage is relevant for risk-stratification in primary biliary cirrhosis. J Hepatol: 2015; 62 S805
23. Silveira M. G., Brunt E. M., Heathcote J., Gores G. J., Lindor K. D., Mayo M. J. American Association for the Study of Liver Diseases endpoints conference: Design and endpoints for clinical trials in primary biliary cirrhosis. Hepatology: 2010; 52 1 349 359
24. Kuiper E. M., Hansen B. E., de Vries R. A., et al. Dutch PBC Study Group. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology: 2009; 136 4 1281 1287
25. Kumagi T., Guindi M., Fischer S. E., et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol: 2010; 105 10 2186 2194
26. Carbone M., Sharp S. J., Flack S., et al. and the members of the UK-PBC Consortium. The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cirrhosis. Hepatology: 2015;;Jul 29. doi:10.1002/hep.28017
27. Lammers W. J., Hirschfield G. M., Corpechot C., et al. Global PBC Study Group. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy. Gastroenterology: 2015; 149 7 1804 1812.e4
28. Angulo P., Lindor K. D., Therneau T. M., et al. Utilization of the Mayo Risk Score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. Liver: 1999; 19 2 115 121
29. Azemoto N., Kumagi T., Abe M., et al. Biochemical response to ursodeoxycholic acid predicts long-term outcome in Japanese patients with primary biliary cirrhosis. Hepatol Res: 2011; 41 4 310 317
30. Poupon R. E., Bonnand A. M., Chrétien Y., Poupon R.; The UDCA-PBC Study Group. Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Hepatology: 1999; 29 6 1668 1671
31. Prince M. I., James O. F., Holland N. P., Jones D. E. Validation of a fatigue impact score in primary biliary cirrhosis: Towards a standard for clinical and trial use. J Hepatol: 2000; 32 3 368 373
32. Angulo P., Jorgensen R. A., Keach J. C., Dickson E. R., Smith C., Lindor K. D. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology: 2000; 31 2 318 323
33. Rautiainen H., Kärkkäinen P., Karvonen A. L., et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: A three-year randomized trial. Hepatology: 2005; 41 4 747 752
34. Rabahi N., Chrétien Y., Gaouar F., et al. Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone. Gastroenterol Clin Biol: 2010; 34 4-5 283 287
35. Parés A., Guañabens N. Osteoporosis in primary biliary cirrhosis: Pathogenesis and treatment. Clin Liver Dis: 2008; 12 2 407 424
36. Hempfling W., Grunhage F., Dilger K., Reichel C., Beuers U., Sauerbruch T. Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology: 2003; 38 1 196 202
37. Rautiainen H., Karvonen A. L., Karkkainen P., et al. 6 year follow up of liver histology after budesonide + UDCA combination therapy in PBC compared with UDCA monoterapy. J Hepatol: 2011; 54 (Suppl): S517
38. Rautiainen H., Färkkilä M., Neuvonen M., et al. Pharmacokinetics and bone effects of budesonide in primary biliary cirrhosis. Aliment Pharmacol Ther: 2006; 24 11-12 1545 1552
39. Schade R. W., Demacker P. N., van T Laar A. Letter: Reduction of serum-alkaline-phosphatase by clofibrate. Lancet: 1975; 1 7911 862 863
40. Schaffner F. Paradoxical elevation of serum cholesterol by clofibrate in patients with primary biliary cirrhosis. Gastroenterology: 1969; 57 3 253 255
41. Nakai S., Masaki T., Kurokohchi K., Deguchi A., Nishioka M. Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: A preliminary study. Am J Gastroenterol: 2000; 95 1 326 327
42. Kurihara T., Niimi A., Maeda A., Shigemoto M., Yamashita K. Bezafibrate in the treatment of primary biliary cirrhosis: Comparison with ursodeoxycholic acid. Am J Gastroenterol: 2000; 95 10 2990 2992
43. Kanda T., Yokosuka O., Imazeki F., Saisho H. Bezafibrate treatment: A new medical approach for PBC patients? J Gastroenterol: 2003; 38 6 573 578
44. Itakura J., Izumi N., Nishimura Y., et al. Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis. Hepatol Res: 2004; 29 4 216 222
45. Levy C., Peter J. A., Nelson D. R., et al. Pilot study: Fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Aliment Pharmacol Ther: 2011; 33 2 235 242
46. Lens S., Leoz M., Nazal L., Bruguera M., Parés A. Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid. Liver Int: 2014; 34 2 197 203
47. Cuperus F. J., Halilbasic E., Trauner M. Fibrate treatment for primary biliary cirrhosis. Curr Opin Gastroenterol: 2014; 30 3 279 286
48. Ghonem N. S., Assis D. N., Boyer J. L. Fibrates and cholestasis. Hepatology: 2015; 62 2 635 643
49. Honda A., Ikegami T., Nakamuta M., et al. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. Hepatology: 2013; 57 5 1931 1941
50. Tanaka A., Hirohara J., Nakanuma Y., Tsubouchi H., Takikawa H. Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA. J Gastroenterol: 2015; 50 6 675 682
51. Hosonuma K., Sato K., Yamazaki Y., et al. A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia. Am J Gastroenterol: 2015; 110 3 423 431
52. Trauner M., Boyer J. L. Bile salt transporters: Molecular characterization, function, and regulation. Physiol Rev: 2003; 83 2 633 671
53. Trauner M. The nuclear bile acid receptor FXR as a novel therapeutic target in cholestatic liver diseases: Hype or hope? Hepatology: 2004; 40 1 260 263
54. Pellicciari R., Fiorucci S., Camaioni E., et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem: 2002; 45 17 3569 3572
55. Fiorucci S., Clerici C., Antonelli E., et al. Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J Pharmacol Exp Ther: 2005; 313 2 604 612
56. Kowdley K. V., Jones D., Luketic V., et al. An international study evaluating the farnesoid X receptor agonist obeticholic acid as monotherapy in PBC. J Hepatol: 2011; 54 S13
57. Nevens F., Andreone P., Mazzella G., et al. The first primary biliary cirrhosis (PBC) phase 3 trial in two decades - an international study of the FXR agonist obeticholic acid in PBC patients. J Hepatol: 2014; 60 S525
58. Mason A., Luketic V. A., Lindor K., et al. Farnesoid - X receptor agonists: A new class of drugs for the treatment of PBC? An international study evaluating the addition of obeticholic acid (INT - 747) to ursodeoxycholic acid. Hepatology: 2010; 52 357A
59. Neuschwander-Tetri B. A., Loomba R., Sanyal A. J., et al. NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial. Lancet: 2015; 385 9972 956 965
60. Efe C., Ozaslan E., Kav T., et al. Liver fibrosis may reduce the efficacy of budesonide in the treatment of autoimmune hepatitis and overlap syndrome. Autoimmun Rev: 2012; 11 5 330 334
61. Ballot E., Bandin O., Chazouilleres O., Johanet C., Poupon R. Immune response to lipopolysaccharide in primary biliary cirrhosis and autoimmune diseases. J Autoimmun: 2004; 22 2 153 158
62. Calmus Y., Gane P., Rouger P., Poupon R. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: Effect of ursodeoxycholic acid. Hepatology: 1990; 11 1 12 15
63. Koga H., Sakisaka S., Ohishi M., Sata M., Tanikawa K. Nuclear DNA fragmentation and expression of Bcl-2 in primary biliary cirrhosis. Hepatology: 1997; 25 5 1077 1084
64. Miura T., Ouchida R., Yoshikawa N., et al. Functional modulation of the glucocorticoid receptor and suppression of NF-kappaB-dependent transcription by ursodeoxycholic acid. J Biol Chem: 2001; 276 50 47371 47378
65. Ikegami T., Matsuzaki Y., Fukushima S., et al. Suppressive effect of ursodeoxycholic acid on type IIA phospholipase A2 expression in HepG2 cells. Hepatology: 2005; 41 4 896 905
66. Schaap F. G., Trauner M., Jansen P. L. Bile acid receptors as targets for drug development. Nat Rev Gastroenterol Hepatol: 2014; 11 1 55 67
67. Luo J., Ko B., To C., et al. Hepatoprotective effects of NGM282 compared to obeticholic acid and bezafibrate in mouse models of cholestasis. J Hepatol: 2014; 60 (Suppl): S531
68. Mayo M., Wigg A., Roberts S., et al. NGM282, a novel variant of FGF-19, demonstrates biologic activity in primary biliary cirrhosis patients with an incomplete response to ursodeoxycholic acid: Results of a phase 2 multicenter, randomized, double blinded, placebo controlled trial. Hepatology: 2015; 62 263A
69. Baker A., Kelly D., McClean P., et al. LO4: A phase 2, randomized, placebo-controlled study (IMAGO) of LUM001, a novel inhibitor of the apical sodium-dependent bile acid transporter (ASBT), in paediatric patients with Alagille syndrome (ALGS). J Hepatol: 2015; 62 (Suppl): S259
70. 3 output. Hepatology: 2011; 54 4 1303 1312
71. Hofmann A. F., Zakko S. F., Lira M., et al. Novel biotransformation and physiological properties of norursodeoxycholic acid in humans. Hepatology: 2005; 42 6 1391 1398
72. Hirschfield G., Gershwin M., Strauss R., et al. Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: A proof-of-concept study. Hepatology: 2015;; doi:10.1002/hep.28359
73. Tsuda M., Moritoki Y., Lian Z. X., et al. Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Hepatology: 2012; 55 2 512 521
74. Myers R. P., Swain M. G., Lee S. S., Shaheen A. A., Burak K. W. B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid. Am J Gastroenterol: 2013; 108 6 933 941
75. Hochrath K., Stokes C. S., Geisel J., et al. Vitamin D modulates biliary fibrosis in ABCB4-deficient mice. Hepatol Int: 2014; 8 3 443 452
76. Guo G. Y., Shi Y. Q., Wang L., et al. Serum vitamin D level is associated with disease severity and response to ursodeoxycholic acid in primary biliary cirrhosis. Aliment Pharmacol Ther: 2015; 42 2 221 230
77. Corpechot C., Gaouar F., Chazouilleres O., et al. Is biochemical response to ursodeoxycholic acid therapy impacted by vitamin D plasma level in patients with pri- mary biliary cirrhosis? Hepatology: 2012; 56 1137A
78. Patsenker E., Popov Y., Stickel F., Jonczyk A., Goodman S. L., Schuppan D. Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression. Gastroenterology: 2008; 135 2 660 670